



US006291505B1

**(12) United States Patent**  
Huebner et al.

**(10) Patent No.: US 6,291,505 B1**  
**(45) Date of Patent: Sep. 18, 2001**

**(54) ESTROGEN RECEPTOR MODULATORS**

**(75) Inventors:** Verena D. Huebner, Benicia; Xiaodong Lin, Walnut Creek, both of CA (US); Ian James, Rowville (AU); Liya Chen, East Brunswick, NJ (US); Manoj Desai, Pleasant Hill, CA (US); Beata Krywult, Armadale (AU); Rajinder Singh, San Francisco; Liang Wang, Lafayette, both of CA (US)

**(73) Assignee:** Chiron Corporation, Emeryville, CA (US)

**(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

**(21) Appl. No.: 09/369,747**

**(22) Filed:** Aug. 6, 1999

**Related U.S. Application Data**

**(60) Provisional application No. 60/095,772, filed on Aug. 7, 1998.**

**(51) Int. Cl.<sup>7</sup> .....** A61K 31/415; A61P 19/10; C07D 231/12

**(52) U.S. Cl. ....** 514/406; 548/377.1

**(58) Field of Search .....** 548/377.1; 514/406

**(56) References Cited****U.S. PATENT DOCUMENTS**

4,112,108 9/1978 Nadelson .  
4,229,204 10/1980 Howe .

**FOREIGN PATENT DOCUMENTS**

2441504 A1	8/1974 (DE) .....	C07D/231/12
31 19727 A1	5/1981 (DE) .	
41 26543 A1	2/1993 (DE) .....	C07D/231/54
42 30 839 A1	3/1993 (DE) .....	C08G/65/40
44 08 084 A1	3/1994 (DE) .	
0 026 928	3/1980 (EP) .	
0 442 448 A2	2/1991 (EP) .....	C07D/207/327
0 623 603 A1	10/1993 (EP) .	
2104932	8/1970 (FR) .....	A61D/27/00
WO 96/25405	8/1996 (WO) .	
WO 97/01551	1/1997 (WO) .....	C07D/403/04
WO 00/75131	12/2000 (WO) .	

**OTHER PUBLICATIONS**

Amme, Omar et al.; "Synthesis, binding affinities and uterotrophic activity of some 2-substituted estradiol and ring-A-fused pyrone derivatives", XP-002136351, *Eur J Med Chem* 29:25-32 (1994).  
Duncan, Dean C. et al.; "The Preparation of N-Carboalkoxypyrazoles and N-Phenylpyrazoles from C(α)-Dianions of Carboalkoxyhydrazones and Phenylhydrazones", XP-002136350, *J. Heterocyclic Chem.*, 24:555 (1987).

Fink, Brian E. et al.; "Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens", XP-000905542, *Chemistry & Biology*, 6:205-219 (Apr. 1999).

Sun, Jun et al.; "Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-α or Estrogen Receptor-β", XP-000908867, *Endocrinology*, vol. 140, 2:800-804 (1999).

Wachter, Gerald A. et al.; "Tetrahydronaphthalenes: Influence of Heterocyclic Substituents on Inhibition of Steroidogenic Enzymes P450 arom and P450 17", XP-002099563, *J. Med. Chem.*, 39:834-841 (1996).

Meisenheimer et al., "Uber Triaryl-isoxazole", *Chemische Berichte*, (1921)3195-3206.

Krishna et al., "Synthesis and Physiological Activity of 3-Hydroxy-Phenyl-5-Aryl Isoxazoles", *Chemical Abstracts*, (1973) 79(13):487.

Yamawaki et al., "Synthesis and Biological Activity of the Metabolites of [3,4-Bis(4-Methoxyphenyl)-5-Isoxazolyl] Acetic Acid", *Chemical and Pharmaceutical Bulletin*, (1988) 36(8):3142-3146.

Kim et al., "Reactions of 5-Substituted 3-Alkyl- and 3-Aryl-Isoxazoles with Tetrasulfur Tetranitride Antimony Pentachloride Complex (S<sub>4</sub>N<sub>4</sub>SbCl<sub>5</sub>): Complete Regioselective Formation of 4-Substituted 3-Acyl- and 3-Aroyl-1,2,5-Thiadiazoles and their Mechanism of Formation", *Journal of the Chemical Society*, (1998) 14:2175-2180.

Mohan et al., "Search for Physiologically Active Compounds. XIV Synthesis of some 3,5-Disubstituted Isoxazoles and their Physiological Activity", *Chemical Abstracts*, (1968) 69(11):4107.

Wrobel et al., "Conversion of 1-(O-Nitroaryl) Alkyl P-Tolysulfones into Isoxazoles", *Heterocycles*, (1995) 40(1):187-190.

Kasturi et al., "Reaction of Spironaphthalenones with Hydroxylamine Hydrochloride: Part IV", *Tetrahedron*, (1995) 51(10):3051-3060.

**Primary Examiner—Robert W. Ramsuer**

**(74) Attorney, Agent, or Firm—David P. Lentini; Robin Teskin; Robert P. Blackburn**

**(57) ABSTRACT**

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

**12 Claims, No Drawings**